New criteria to predict LATE-NC in the clinical setting: Probable/Possible LATE and LANS DOI
Peter T. Nelson

Journal of Neuropathology & Experimental Neurology, Год журнала: 2024, Номер 84(1), С. 2 - 7

Опубликована: Окт. 23, 2024

Abstract This review discusses terminology recently proposed for the classification of dementia and, more specifically, nosology related to aging-associated TDP-43 pathology: limbic-predominant age-related encephalopathy (LATE), and amnestic neurodegenerative syndrome (LANS). While “gold standard” these clinical conditions is still LATE neuropathologic changes (LATE-NC), criteria biomarkers are evolving. The newly rubrics discussed with emphasis on need that acknowledges distinctions between syndrome-, molecular biomarker-, pathologically defined disease concepts. As further progress made research into specific biomarker-based detection prediction proteinopathy in setting, definitions “Probable” “Possible” likely become useful clinically. For people interested pathological diagnoses or basic LATE-NC, relevant remains unchanged by criteria.

Язык: Английский

Role of tau versus TDP‐43 pathology on medial temporal lobe atrophy in aging and Alzheimer's disease DOI Creative Commons
Laura Wisse, Anika Wuestefeld,

Melissa Murray

и другие.

Alzheimer s & Dementia, Год журнала: 2025, Номер 21(2)

Опубликована: Фев. 1, 2025

Abstract Hippocampal atrophy on magnetic resonance imaging is an important biomarker in Alzheimer's disease (AD). While hippocampal was thought to result from tau tangles AD, different neuropathologies can lead atrophy, especially TAR DNA‐binding protein 43 (TDP‐43) pathology. In this narrative review, we evaluate existing studies the relative contribution of and TDP‐43 pathology medial temporal lobe (MTL) atrophy. We report a clear association both neuropathology with MTL even after correcting for other neuropathologies. Next, discuss potential synergism between timing effects Finally, avenues future research will be discussed. A better understanding interplay their effect help development more specific biomarkers limbic‐predominant age‐related encephalopathy pinpointing optimal testing anti‐tau anti‐TDP‐43 treatments trials. Highlights Both contribute There positive potentially synergism. It unclear if have additive or synergistic The remains unclear. Clarifying improve biomarkers.

Язык: Английский

Процитировано

1
Sex/gender differences in the clinical trajectory of Alzheimer’s disease: Insights into diagnosis and cognitive reserve DOI Creative Commons

Sheina Emrani,

Erin E. Sundermann

Frontiers in Neuroendocrinology, Год журнала: 2025, Номер 77, С. 101184 - 101184

Опубликована: Фев. 13, 2025

Язык: Английский

Процитировано

0
LATE-NC Stage 3: a diagnostic rubric to differentiate severe LATE-NC from FTLD-TDP DOI Creative Commons
Ryan K. Shahidehpour, Yuriko Katsumata, Dennis W. Dickson

и другие.

Acta Neuropathologica, Год журнала: 2025, Номер 149(1)

Опубликована: Апрель 28, 2025

A diagnostic rubric is required to distinguish between limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) and frontotemporal lobar degeneration with inclusions (FTLD-TDP). In LATE-NC Stage 3, proteinopathy present in the middle frontal gyrus (MFG), thus posing a potential challenge differentiating these severe cases from FTLD-TDP. 3 other proteinopathies were analyzed University of Kentucky (total n = 514 pathology assessed), The 90+ Study at California Irvine (n 458), Mayo Clinic 5067) brain banks. Digital was used quantify burden select subset 51), complemented by previously-described manual counting method expert examinations evaluate qualitative features such as FTLD-TDP types subtypes neuronal cytoplasmic (NCIs). To clinical genetic characteristics data National Alzheimer's Coordinating Center (NACC) Neuropathology Data set correlated findings Disease Genetics Consortium (ADGC). When using quantification MFG criterion, more than 90% could be classified either or Diagnostically challenging scenarios included Type B relatively mild novel non-LATE-NC, non-FTLD-TDP pathologic subtype pathology. Taking pitfalls into account, classification schema developed that correctly diagnose all cases. There no difference disease pathological load Stages 2 versus 3. analyses, GRN (rs5848) risk allele preferentially associated whereas TMEM106B APOE risk-associated variants not. conclusion, differentiated reliably TDP-43-opathies, based on data-driven rubric.

Язык: Английский

Процитировано

0
Antiamyloid Monoclonal Antibodies in Alzheimer’s Disease, Part 1: Patient Selection DOI
James R. Bateman, Tara C. Carlisle, Yanghong Yang

и другие.

Journal of Neuropsychiatry, Год журнала: 2025, Номер unknown

Опубликована: Май 5, 2025

The availability of monoclonal antibodies directed against amyloid beta, for use as disease-modifying therapies Alzheimer's disease (AD), represented a major shift in the field AD research and treatment. U.S. Food Drug Administration approvals antibody-based medications lecanemab and, more recently, donanemab provide clinicians with two antiamyloid therapy (AAT) options targeting early symptomatic AD. emergence AAT has made careful biomarker-informed diagnosis paramount, which was once reserved highly specialized centers settings. Patient selection is complex, although appropriate-use recommendations have been published, caring patients across United States face uncertainty when trying to align clinical trial criteria, recommendations, real-world clinic. Practical issues patient well health care systemic challenges implementation are considered part 1 2, respectively, this two-part Treatment Behavioral Neurology & Neuropsychiatry commentary on these from American Neuropsychiatric Association Dementia Special Interest Group.

Язык: Английский

Процитировано

0
Spatial navigation deficits in early Alzheimer’s disease: the role of biomarkers and APOE genotype DOI Creative Commons

Martina Laczó,

Zuzana Svacova,

Ondřej Lerch

и другие.

Journal of Neurology, Год журнала: 2025, Номер 272(6)

Опубликована: Июнь 1, 2025

Язык: Английский

Процитировано

0
New criteria to predict LATE-NC in the clinical setting: Probable/Possible LATE and LANS DOI
Peter T. Nelson

Journal of Neuropathology & Experimental Neurology, Год журнала: 2024, Номер 84(1), С. 2 - 7

Опубликована: Окт. 23, 2024

Abstract This review discusses terminology recently proposed for the classification of dementia and, more specifically, nosology related to aging-associated TDP-43 pathology: limbic-predominant age-related encephalopathy (LATE), and amnestic neurodegenerative syndrome (LANS). While “gold standard” these clinical conditions is still LATE neuropathologic changes (LATE-NC), criteria biomarkers are evolving. The newly rubrics discussed with emphasis on need that acknowledges distinctions between syndrome-, molecular biomarker-, pathologically defined disease concepts. As further progress made research into specific biomarker-based detection prediction proteinopathy in setting, definitions “Probable” “Possible” likely become useful clinically. For people interested pathological diagnoses or basic LATE-NC, relevant remains unchanged by criteria.

Язык: Английский

Процитировано

1